Article
Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.
PloS one - 1 Jan 2014
Sølund Christina, Krarup Henrik, Ramirez Santseharay, Thielsen Peter, Røge Birgit T, Lunding Suzanne, Barfod Toke S, Madsen Lone G, Tarp Britta, Christensen Peer B, Gerstoft Jan, Laursen Alex L, Bukh Jens, Weis Nina
Abstract excerpt
BACKGROUND AND AIMS: The first standard of care in treatment of chronic HCV genotype 1 infection involving directly acting antivirals was protease inhibitors telaprevir or boceprevir combined with pegylated-interferon and ribavirin (triple therapy). Phase III studies include highly selected patients. Thus, treatment response and development of viral resistance during triple therapy in a routine clinical setting...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.